EDEN PRAIRIE, Minn.,
June 2, 2021 /PRNewswire/
-- NeuroOne Medical Technologies Corporation (NASDAQ:
NMTC; NeuroOne or the Company), a medical technology company
focused on improving surgical care options and outcomes for
patients suffering from neurological disorders, announces today the
formation of a six member advisory board of leading neurosurgeons
to assist in the completion of development of a radio frequency
ablation electrode intended to record and ablate brain tissue
linked to causing seizure activity.
The six members that have been appointed to the advisory board
are as follows:
- Dr. Daniel Couture, Wake Forest
- Dr. Gerald Grant, Stanford University Medical Center
- Dr. Bob Gross, Emory University
- Dr. Zachary Levine, Holy Cross
Health, George Washington
- Dr. Guy McKhann, New York
Presbyterian Hospital, Columbia
- Dr. Jamie Van Gompel, Mayo
NeuroOne CEO Dave Rosa says, "We
are honored to have an opportunity to partner with such
distinguished neurosurgeons who I believe will be extremely helpful
in accelerating our ablation electrode technology program. Their
experience in the field will be indispensable to the Company in
developing a product that allows neurologists to record brain
activity and ablate targeted brain tissue in the same procedure.
The electrode is also expected to save time, cost and potentially
improve outcomes, adding value to both patients and physicians that
could benefit from this technology."
NeuroOne Medical Technologies Corporation is a developmental stage
company committed to providing minimally invasive and hi-definition
solutions for EEG recording, brain stimulation and ablation
solutions for patients suffering from epilepsy, Parkinson's
disease, dystonia, essential tremors, chronic pain due to failed
back surgeries and other related neurological disorders that may
improve patient outcomes and reduce procedural costs. For more
information, visit https://www.n1mtc.com .
On February 23, 2021, the Company announced it had
successfully met the first performance milestone in the
distribution and development agreement signed with Zimmer Biomet
on July 20, 2020 . In addition to acquiring exclusive
global distribution rights to NeuroOne's Evo™ (Evo) patented
electrode technology, the partnership also offered the potential
for NeuroOne to earn back-end milestone payments if certain events
were met within a specified time frame.
NeuroOne received FDA clearance for its Evo cortical technology
in November 2019.
In partnership with Mayo Clinic, Wisconsin Alumni Research
Foundation (WARF) and other prominent academic medical centers, the
Company began developing its cortical electrode technology in 2015.
The Company initially focused its efforts on the epilepsy and
intraoperative tumor monitoring markets. NeuroOne intends to
continue to develop the technology for use in therapeutic
applications for Parkinson's disease, epilepsy and pain management
due to failed back surgery procedures.
Forward Looking Statements
This press release contains forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities Exchange Act of 1934, as amended.
Except for statements of historical fact, any information contained
in this presentation may be a forward–looking statement that
reflects NeuroOne's current views about future events and are
subject to known and unknown risks, uncertainties and other factors
that may cause our actual results, levels of activity, performance
or achievements to be materially different from the information
expressed or implied by these forward-looking statements. In some
cases, you can identify forward–looking statements by the words
"may," "might," "will," "could," "would," "should," "expect,"
"intend," "plan," "objective," "anticipate," "believe," "estimate,"
"predict," "project," "potential," "target," "seek," "contemplate,"
"continue" and "ongoing," or the negative of these terms, or other
comparable terminology intended to identify statements about the
future. Forward–looking statements may include statements regarding
the development of the Company's ablation electrode technology
program, the receipt of regulatory clearance, the timing and extent
of product launch and commercialization of the technology, what the
future may hold for electrical stimulation and NeuroOne's potential
role, business strategy, market size, potential growth
opportunities, future operations, future efficiencies, and other
financial and operating information. Although NeuroOne believes
that we have a reasonable basis for each forward-looking statement,
we caution you that these statements are based on a combination of
facts and factors currently known by us and our expectations of the
future, about which we cannot be certain. Our actual future results
may be materially different from what we expect due to factors
largely outside our control, including risks that the partnership
with Zimmer Biomet may not facilitate the commercialization or
market acceptance of our technology; risks that our sEEG electrodes
may not be ready for commercialization in a timely manner or at
all; risks that our technology will not perform as expected based
on results of our pre-clinical and clinical trials, our ability to
raise additional funds, uncertainties inherent in the development
process of our technology, changes in regulatory requirements or
decisions of regulatory authorities, the size and growth potential
of the markets for our technology, clinical trial patient
enrollment, the results of clinical trials, our ability to protect
our intellectual property rights and other risks, uncertainties and
assumptions, including those described under the heading "Risk
Factors" in our filings with the Securities and Exchange
Commission. These forward–looking statements speak only as of the
date of this press release and NeuroOne undertakes no obligation to
revise or update any forward–looking statements for any reason,
even if new information becomes available in the future.
"Caution: Federal law restricts this device to sale by or on the
order of a physician"
View original content to download
SOURCE NeuroOne Medical Technologies Corporation